Human variability and noncancer risk assessment - An analysis of the default uncertainty factor

Regulatory Toxicology and Pharmacology

Volumn 27, Issue 1 I, 1998, Pages 3-20

  Renwick, A G ^a   Lazarus, N R ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b OPEN UNIVERSITY   (United Kingdom)

Author keywords

Human variability; Interindividual differences; Toxicodynamics; Toxicokinetics; Uncertainty factor

Indexed keywords

ARTICLE; CANCER; CANCER RISK; DATA ANALYSIS; DATA BASE; HEALTH HAZARD; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0031809917     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1997.1195     Document Type: Article

References (142)

1. Aarons, L. (1996). Population approaches/sparse data analysis for human variability in kinetics and dynamics. Environ. Toxicol. Pharmacol. 2, 197-199.
2. Ahsan, C. H., Renwick, A. G., Waller, D. G., Challenor, V. F., George, C. F., and Amanullah, M. (1993). The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin. Pharmacol. Ther. 54, 329-338.
3. Amon, L, Amon, K, Scharp, H., Franke, G., and Nagel, F. (1983). Disposition kinetics of metronidazole in children. Ear. J. Clin. Pharmacol. 24, 113-119.
4. Barrett, J. S., Murphy, G., Peerlinck, K, De-Lepeleire, I., Gould, R. J., Panebianco, D., Hand, E., Deckmyn, H., Vermylen, J., and Arnout, J. (1994). Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-Ilb/IIIa receptor antagonist, in healthy men. Clin. Pharmacol. Ther. 56, 377-388.
5. Bateman, D. N. (1983). Clinical pharmacokinetics of metoclopramide. Clin. Pharmacokinet. 8, 523-529.
6. Bertilsson, L., Henthorn, T. K, Sanz, E., Tybring, G., Säwe, J., and Viltén, T. (1989). Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin but not debrisoquin hydroxylation phenotype. Clin. Pharmacol. Ther. 45, 348-355.
7. Blackwell, C. P., and Harding, S. M. (1989). The clinical pharmacology of ondansetron. Eur. J. Cancer Clin. Oncol. 25, S21-S24.
8. Blain, P. G., Mucklow, J. C., Bacon, C. J., and Rawlins, M. D. (1981). Pharmacokinetics of phenytoin in children. Br. J. Clin. Pharmacol. 12, 659-661.
9. Blychert, E., Edgar, B., Elmfeldt, D., and Hedner, T. (1991). A population study of the pharmacokinetics of felodipine. Br. J. Clin. Pharmacol. 31, 15-24.
10. Blychert, E., Edgar, B., Elmfeldt, D., and Hedner, T. (1992). Plasma concentration-effect relationships for felodipine: A meta analysis. Clin. Pharmacol. Ther. 52, 80-89.
11. 2-adrenoceptor antagonism in asthmatic patients by pharmacokinetic-pharmacodynamic modelling. Pulmonary Pharmacol. 5, 31-38.
12. Braat, M. C. P., Jonkers, R. E., Bel, E. H., and Van Boxtel, C. J. (1992b). Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers. Clin. Pharmacokinet. 22, 231-237.
13. Buss, N. E., Renwick, A. G., Donaldson, K. M., and George, C. F. (1992). The metabolism of cyclamate to cyclohexylamine and its cardiovascular consequences in human volunteers. Toxicol. Appl. Pharmacol. 115, 199-210.
14. Buss, N. E., Tembe, E. A., Prendergast, B. D., Renwick, A. G., and George, C. F. (1994). The teratogenic metabolites of vitamin A in women following supplements and liver. Hum. Exp. Toxicol. 13, 33-43.
15. Cadórniga, R., Molina, I. T., Pastoriza, P., Negro, S., Evora, C. M., and Gutierrez, J. A. (1990). Pharmacokinetics of cefroxadine after infusion to healthy volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 28, 435-439.
16. Calabrese, E. J. (1985). Uncertainty factors and interindividual variation. Regul. Toxicol. Pharmacol. 5, 190-196.
17. Calabrese, E. J., Beck, B. D., and Chappell, W. R. (1992). Does the animal to human uncertainty factor incorporate interspecies differences in surface area? Regul. Toxicol. Pharmacol. 15, 172-179.
18. Capon, D. A., Bochner, F., Kerry, N., Mikus, G., Danzo, C., and Somogyi, A. A. (1996). The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin. Pharmacol. Ther. 60, 295-307.
19. Carosella, L., Menichelli, P., Alimenti, M., Zuccala, G., Gemma, A., Cocchi, A., and Carbonin, P. U. (1989). Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses. Cardiovasc. Drugs Ther. 3, 417-425.
20. Chan, K., Tse, J., Jennings, F., and Orme, M. L'E. (1990). Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in Caucasians, Chinese and Indian subjects. Methods Find. Exp. Clin. Pharmacol. 12, 61-67.
21. Chiba, K, Ishizaki, T., Miura, H., and Minagawa, K. (1980). Michaelis-Menton pharmacokinetics of diphenylhydantoin and application in the pediatric age patients. J. Pediatr. 96, 479-484.
22. Chu, S-y., Wilson, D. S., Guay, D. R. P., and Craft, C. (1992). Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J. Clin. Pharmacol. 32, 1045-1049.
23. Criscuoli, M., Lippi, A., Mengozzi, G., Sardelli, G., Subissi, A., and Giachetti, A. (1993). Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs and humans. Drug Metab. Dispos. 21, 835-840.
24. Critchley, J. A. J. H., Nimmo, G. R., Gregson, C. A., Woolhouse, N. M., and Prescott, L. F. (1986). Inter-subject and ethnic differences in paracetamol metabolism. Br. J. Clin. Pharmacol. 22, 649-657.
25. Day, R. O., Graham, G. G., Bieri, D., Brown, M., Cairns, D., Harris, G., Hounsell, J., Platt-Hepworth, S., Reeve, R., Sambrook, P. N., and Smith, J. (1989). Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Br. J. Clin. Pharmacol. 28, 695-702.
26. de Groot, A. N. J. A., Vree, T. B., Hekster, Y. A., van den BiggelaarMartea, M., van Dongen, P. W. J., and van Roosmalen, J. (1994). Pharmacokinetics and bioavailability of oral ergometrine in male volunteers. Biopharm. Drug Dispos. 15, 65-73.
27. de Jong, J., Geijssen, G. J., Munniksma, C. N., Vermerken, J. B., and van der Vijgh, W. J. F. (1992). Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. J. Clin. Oncol. 10, 1897-1906.
28. Dias, V. C., Weir, S. J., and Ellenbogen, K. A. (1992). Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. Circulation 86, 1421-1428.
29. Dingemanse, J., Jorga, K. M., Schmitt, M., Gieschke, R., Fotteler, B., Zurcher, G., Da Prada, M., and van Brummelen, P. (1995). Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther. 57, 508-517.
30. Donnelly, R., Elliott, H. L., Meredith, P. A., Kelman, A. W., and Reid, J. L. (1988). Nifedipine: Individual responses and concentration-effect relationships. Hypertension 12, 443-449.
31. Donnelly, R., Elliott, H. L., Meredith, P. A., and Reid, J. L. (1989). Concentration-effect relationships and individual responses to doxazosin in essential hypertension. Br. J. Clin. Pharmacol. 28, 517-526.
32. Donnelly, R., Meredith, P. A., Elliott, H. L., and Reid, J. L. (1990). Kinetic-dynamic relations and individual responses to enalapril. Hypertension 15, 301-309.
33. Donnelly, R., Meredith, P. A., Miller, S. H. K, Howie, C. A., and Elliott, H. L. (1993). Pharmacodynamic modeling of the antihypertensive response to almodipine. Clin. Pharmacol. Ther. 54, 303-310.
34. Dourson, M. L., and Stara, J. F. (1983). Regulatory history and experimental support of uncertainty (safety) factors. Regul. Toxicol. Pharmacol. 3, 224-228.
35. Dourson, M. L., Felter, S. P., and Robinson, D. (1996). Evolution of science-based uncertainty factors for noncancer risk assessment. Regul. Toxicol. Pharmacol. 24, 108-120.
36. Ducharme, J., Varin, F., Bevan, D. R., and Donati, F. (1993). Importance of early blood sampling on vecuronium pharmacokinetic and pharmacodynamic parameters. Clin. Pharmacokinet. 24, 507-518.
37. Falk, A. A., Hagberg, M. T., Löf, A. E., Wigaeus-Hjelm, E. M., and Zhiping, W. (1990). Uptake, distribution and elimination of α-pinene in man after exposure by inhalation. Scand. J. Work Environ. Health 16, 372-378.
38. Fischler, M., Bonnet, F., Trang, H., Jacob, L., Levron, J. C., Flaisler, B., and Vourch, G. (1986). The pharmacokinetics of droperidol in anesthetised patients. Anaesthesiology 64, 486-489.
39. Fisher, L. E., Ludwig, E. A., Wald, J. A., Sloan, R. R., Middleton, E., and Jusko, W. J. (1992). Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 AM versus 4 PM. Clin. Pharmacol. Ther. 51, 677-688.
40. Fleishaker, J. C., Friedman, H., and Pollock, S. R. (1991a). Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers. Pharmacol. Res. 8, 162-167.
41. Fleishaker, J. C., Smith, T. C., Friedman, H., and Phillips, J. P. (1991b). N-Desmethyladinazolam pharmacokinetics and behavioral effects following administration of 10-50 mg oral doses in healthy volunteers. Psychopharmacology 105, 181-185.
42. Fraser, H. S., Mucklow, J. C., Bulpitt, C. J., Kahn, C., Mould, G., and Dollery, C. T. (1979). Environmental factors affecting antipyrine metabolism in London factory and office workers. Br. J. Clin. Pharmacol. 7, 237-243.
43. Friedman, H., Redmond D. E., and Greenblatt, D. J. (1991). Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African green monkeys. Psychopharmacology 104,103-105.
44. Fukuhara, S., Echizen, H., Naito, M., Ishikawa, S., Toyama, M., Nagoshi, H., Honda, M., and Ishizaki, T. (1989). An interindividual variability in the sensitivity of atrioventricular node to diltiazem in patients with paroxysmal supraventricular tachycardia. J. Clin. Pharmacol. 29, 102-106.
45. Furukawa, T., Kumai, K, Kubota, T., Hirahata, S., Shimizu, H., Matsui, H., Takahara, T., Aizawa, K-L, Shibata, S., Shimada, A., Yoshino, K., Ishibiki, K., and Kitajima, M. (1993). Experimental and clinical studies on the intraperitoneal administration of cisdiamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers. Surg. Today Jpn. J. Surg. 23, 298-306.
46. Gariepy, L. P., Varin, F., Donati, F., Salib, Y., and Bevan, D. R. (1993). Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. Clin. Pharmacol. Ther. 53, 340-347.
47. Ghoneim, M. M., Korttila, K., Chiang, C-K., Jacobs, L., Schoenwald, R. D., Mewaldt, S. P., and Kayaba, K-O. (1981). Diazepam effects and kinetics in Caucasians and Orientals. Clin. Pharmacol. Ther. 29, 749-756.
48. Girard, P., Saumet, J. L., Dubois, F., and Boissel, J. P. (1993). Pharmacodynamic model of haemodynamic effects of pinacidil in normotensive volunteers. Eur. J. Clin. Pharmacol. 44, 177-182.
49. Graffner, C., Lagerstrom, P-O., and Lundborg, P. (1979). Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. Br. J. Clin. Pharmacol. 8, 469-474.
50. Grahnen, A., Wennerlund, P., Dahlstrom, B., and Eckernas, S-A. (1991). Inter- and intraindividual variability in the concentration-effect (sedation) relationship of flunitrazepam. Br. J. Clin. Pharmacol. 31, 89-92.
51. Gram, L. F., Guerstert, T. W., Grange, S., Vistisen, K., and Brøsen, K. (1995). Moclobemide, a substrate for CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2: A panel study. Clin. Pharmacol. Ther. 57, 670-677.
52. Granneman, G. R., Carpentier, P., Morrison, P. J., and Pernet, A. G. (1991). Pharmacokinetics of temafloxacin in humans after single oral doses. Antimicrob. Agents Chemother. 35, 436-441.
53. Greenblatt, D. J., Abernethy, D. R., Locniskar, A., Ochs, H. R., Harmatz, J. S., and Shader, R. I. (1985). Age, sex and nitrazepam kinetics: Relation to antipyrine disposition. Clin. Pharmacol. Ther. 38, 697-703.
54. Greenblatt, D. J., Ehrenberg, B. L., Gunderman, J., Locniskar, A., Scavone, J. M., Harmatz, J. S., and Shader, R. I. (1989). Pharmacokinetics and electroencephalographic study of intravenous diazepam and midazolam and placebo. Clin. Pharmacol. Ther. 45, 356-365.
55. Griensven, J. M. T., Jusko, W. J., Lernkes, H. H. P. J., Kroon, R., Verhorst, C. J., Chiang, S. T., and Cohen, A. F. (1995). Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin. Pharmacol. Ther. 58, 631-640.
56. Grind, M., Nilsson, M-I., Nilsson, L., Oxenstierna, G., Sedvall, G., and Wahlen, A. (1989). Remoxipride - A new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers. Psychopharmacology 98, 304-309.
57. Grochow, L. B., Noe, D. A., Dole, G. B., Rowinsky, E. K, Ettinger, D. S., Graham, M. L., McGuire, W. P., and Donehower, R. C. (1989). Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: Clinical pharmacology and pharmacodynamics. J. Natl. Cancer Inst. 81, 124-130.
58. Grunwald, Z., Torjman, M., Schieren, H., and Bartkowski, R. R. (1993). The pharmacokinetics of droperidol in anesthetised children. Anaesth. Analg. 76, 1238-1242.
59. Guay, D., Tack, K., and Flor, S. (1991). Safety and pharmacokinetics of single dose intravenous ofloxacin in healthy volunteers. Int. J. Clin. Pharm. Res. 11, 203-209.
60. Gupta, S. K, Ellinwood, E. H., Nikaido, A. M., and Heatherly, D. G. (1990). Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam. Pharm. Res. 7, 570-575.
61. Hamelin, B. A., Turgeon, J., Vallée, F., Bélanger, P-M., Paguet, F., and LeBel, M. (1996). The disposition of fluoxetine but not sertraline is altered in poor metabolisers of debrisoquin. Clin. Pharmacol. Ther. 60, 512-521.
62. Haitis, D., Erdreich, L., and Ballew, M. (1987). Human variability in susceptibility to toxic chemicals: A preliminary analysis of pharmacokinetic data from normal volunteers. Risk Anal. 7, 415-426.
63. Hellriegel, E. T., Bjornsson, T. D., and Hauck, W. W. (1996). Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies. Clin. Pharm. Ther. 60, 601-607.
64. Hill, H. F., Chapman, C. R., Saeger, L .S., Bjurstrom, R., Walter, M. H., Schoene, R. B., and Kippes, M. (1990). Steady-state infusions of opioids in human. II. Concentration-effect relationships and therapeutic margins. Pain 43, 69-79.
65. Högger, P., and Rohdewald, P. (1993). Pharmacokinetics of bromfenac in healthy subjects after single oral administration of 3 different doses. Arneim-Forsch. /Drug Res. 43, 1114-1118.
66. Hoskin, P. J., Hanks, G. W., Aherne, G. W., Chapman, D., Littleton, P., and Filshie, J. (1989). The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Er. J. Clin. Pharmacol. 27, 499-505.
67. 2-receptor antagonist AA-2414 in normal subjects: Population analysis. Clin. Pharmacol. Ther. 55, 441-450.
68. Hutt, A. J., Caldwell, J., and Smith, R. L. (1986). The metabolism of aspirin in man: A population study. Xenobiotica 16, 239-249.
69. Inturrisi, C. E., Portenoy, R. K, Max, M. B., Colburn, W. A., and Foley, K. M. (1990). Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin. Pharmacol. Ther. 47, 565-577.
70. Janku, L, Perlik, F., Tkaczykova, M., and Brodanova, M. (1992). Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects. Eur. J. Clin. Pharmacol. 42, 337-340.
71. Johanson, G., Kronborg, H., Näslund, P. H., and Nordqvist, M. B. (1986). Toxicokinetics of inhaled 2-butoxyethanol (ethylene glycol monobutyl ether) in man. Scand. J. Work Environ. Health 12, 594-602.
72. Johnson, J. A., and Burlew, B. S. (1992). Racial differences in propranolol pharmacokinetics. Clin. Pharmacol. Ther. 51, 495-500.
73. Karlsson, M. O., Post, R. E., Ratain, M. J., and Sheiner, L. B. (1995). A population model for the leukopenic effect of etoposide. Clin. Pharmacol. Ther. 57, 325-334.
74. Kauffman, R. E., and Nelson, M. V. (1992). Effects of age on ibuprofen pharmacokinetics and antipyretic response. J. Pediatr. 121, 969-973.
75. Kearns, G. L., and Reed, M. D. (1989). Clinical pharmacokinetics in infants and children. A reappraisal. Clin. Pharmacokinet. 17(S1), 29-67.
76. Kearns, G. L., Reed, M. D., Jacobs, R. F., Ardite, M., Yogev, R. D., and Blumer, J. L. (1991). Single-dose pharmacokinetics of ceftibuten (SCH39720) in infants and children. Antimicrob. Agents Chemother. 35, 2078-2084.
77. Kharasch, E. D., Thummel, K. E., Mautz, D., and Bosse, S. (1994). Clinical enflurane metabolism by cytochrome P450 2E1. Clin. Pharmacol. Ther. 55, 434-460.
78. Kinirons, M. T., Lang, C. C., He, H. B., Ghebreselasine, K, Shay, S., Robin, D. W., and Wood, A. J. J. (1996). Triazolam pharmacokinetics and pharmacodynamics in Caucasians and South Asians: Ethnicity and CYP3A activity. Er. J. Clin. Pharmacol. 41, 69-72.
79. Kirch, W., Hutt, H-J., and Plänitz, V. (1990). Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J. Clin. Pharmacol. 30, 1088-1095.
80. Klepser, M. E., Marangos, M. N., Patel, K B., Nicolau, D. P., Quintiliani, R., and Nightingale, C. H. (1995). Clinical pharmacokinetics of the newer cephalosporins. Clin. Pharmacokin. 28, 361-384.
81. Koopmans, R., Dingemanse, J., Danhof, M., Horsten, G. P. M., and van Boxtel, C. J. (1988). Pharmacokinetic-pharmacodynamic modelling of midazolam effects on the human central nervous system. Clin. Pharmacol. Ther. 44, 14-22.
82. Kroes, R., Munro, L, and Poulsen, E. (1993). Workshops on the scientific evaluation of the safety factor for the acceptable daily intake (ADI): Editorial summary. Food Addit. Contam. 10, 269-273.
83. LeCoz, F., Funck-Brentano, C., Morell, T., Ghadanfar, M. M., and Jaillon, P. (1995). Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administration of dofetilide on ventricular repolarisation. Clin. Pharmacol. Ther. 57, 533-542.
84. Lehman, A. J., and Fitzhugh, O. G. (1954). 100-Fold margin of safety. Assoc. Food Drug Off. U.S.Q. Bull. 18, 33-35.
85. Lemmens, H. J. M., Burm, A. G. L., Bovill, J. G., Hennis, P. J., and Gladines, M. P. R. R. (1992). Pharmacodynamics of alfentanil. Anesthesiology 76, 65-70.
86. Lemmens, H. J. M., Dyck, J. B., Shafer, S. L., and Stanski, D. R. (1994). Pharmacokinetic-pharmacodynamic modeling in drug development: Application to the investigational opioid trefentanil. Clin. Pharmacol. Ther. 56, 261-271.
87. Lewis, S. C., Lynch, J. R., and Nikiforov, A. I. (1990). A new approach to deriving community exposure guidelines from no-observed-adverse-effect levels. Regul. Toxicol. Pharmacol. 11, 314-330.
88. Lindahl, A., Sandström, R., Ungell, A-L., Abrahamsson, B., Knutson, T. W., Knutson, L., and Lennernäs, H. (1996). Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin. Pharmacol. Ther. 60, 493-503.
89. Lindholm, A., Welsh, M., Alton, C., and Kahan, B. D. (1992). Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability. Clin. Pharmacol. Ther. 52, 359-371.
90. Lu, F. C. (1988). Acceptable daily intake: Inception, evolution, and application. Regul. Toxicol. Pharmacol. 8, 45-60.
91. MacPhee, G. J. A., Howie, C. A., Meredith, P. A., and Elliott, H. L. (1991). The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol. Br. J. Clin. Pharmacol. 32, 591-597.
92. Mandema, J. W., Tuk, B., van Steveninck, A. L., Breimer, D. D., Cohen A. F., and Danhof, M. (1992). Pharmacokinetic-pharmacodynamic modelling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin. Pharmacol. Ther. 51, 715-728.
93. Marlier, R., McAinsh, J., and Cockshott, I. D. (1990). Pharmacokinetics of epanolol in elderly patients with stable angina pectoris. Arzneim-Forsch. /Drug Res. 40, 142-144.
94. Mascher, H., and Kikuta, C. (1993). High-performance liquid chromatographic determination of total thiamine in human plasma for oral bioavailability studies. J. Pharm. Sci. 82, 56-59.
95. McGourty, J. C., Silas, J. H., Fleming, J. J., McBurney, A., and Ward, J. W. (1985). Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. Clin. Pharmacol. Ther. 38, 409-413.
96. Midha, K. K, Chakraborty, B. S., Ganes, D. A., Hawes, E. M., Hubbard, J. W., Keegan, D. L., Korchinski, E. D., and McKay, G. (1989). Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J. Clin. Psychopharmacol. 9, 98-104.
97. Mikus, G., Gross, A. S., Beckmann, J., Hertrampf, R., Gundert-Remy, U., and Eichelbaum, M. (1989). The influence of the sparteine/ debrisoquine phenotype on the disposition of flecainide. Clin. Pharmacol. Ther. 45, 562-567.
98. Miller, A. A., Stewart, C. F., and Tolley, E. A. (1990). Clinical pharmacodynamics of continuous-infusion etoposide. Cancer Chemother. Pharmacol. 25, 361-366.
99. Molajo, A. O., Bennett, D. H., Marlow, H. F., Snow, H. M., and Bastain, W. (1987). The effects and dose-response relationship of xamoterol in patients with ischaemic heart disease. Br. J. Clin. Pharmacol. 24, 373-379.
100. Naumann, B. D., and Weideman, P. A. (1995). Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients. Hum. Ecol. Risk Assess. 1, 590-613.
101. Nielsen, K. K, Brøsen, K, Hansen, M. G. J., and Gram, L. F. (1994). Single-dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin. Pharmacol. Ther. 55, 518-527.
102. Noe, D. A., and Kumor, K. M. (1991). A pharmacokinetic-pharmacodynamic model of heart rate during cocaine administration to humans. Clin. Pharmacol. Ther. 49, 426-432.
103. Novak, E., Griffith, D. L., Paxton, L. M., Metzler, C. M., and Bye, A. (1990). Safety and pharmacokinetics of intravenously administered trospectomycin sulfate. Clin. Ther. 12, 269-280.
104. O'Connell, M. B., Pentel, P. R., and Zimmerman, C. L. (1989). Individual variability in the blood pressure response to intravenous phenylpropanolamine: A pharmacokinetic and pharmacodynamic investigation. Clin. Pharmacol. Ther. 45, 252-259.
105. Paintaud, G., Alván, G., Berninger, E., Gustafsson, L. L., Idrizbegovic, E., Karlsson, K. K., and Wakelkamp, M. (1994). The concentration-effect relationship of quinine-induced hearing impairment. Clin. Pharmacol. Ther. 55, 317-323.
106. Patat, A., le Coz, F., Dubruc, C., Gandon, J-M., Durrieu, G., Cimarosti, L, Jezequel, S., Curet, O., Zieleniuk, L, Allain, H., and Rosenzweig, P. (1996). Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers. J. Clin. Pharmacol. 36, 216-229.
107. Plaud, B., Proost, J. H., Wierda, M. K. H., Barre, J., Debaene, B., and Meistelman, C. (1995). Pharmacokinetics and pharmacodynamics of rocuronium on the vocal cords and the adductor pollicis in human. Clin. Pharmacol. Ther. 58, 185-191.
108. Rau, S. E., Bend, J. R., Arnold, M. O., Tran, L. T., Spence, J. D., and Bailey, D. G. (1997). Grapefruit juice-terfenadine single-dose interaction: Magnitude, mechanism and relevance. Clin. Pharmacol. Ther. 61, 401-409.
109. Renwick, A. G. (1991). Safety factors and establishment of acceptable daily intake. Food Addit. Contam. 8, 135-150.
110. Renwick, A. G. (1993). Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit. Contam. 10, 275-305.
111. Renwick, A. G. (1995). The use of an additional safety or uncertainty factor for nature of toxicity in the estimation of acceptable daily intake and tolerable daily intake values. Regul. Toxicol. Pharmacol. 22, 250-261.
112. Renwick, A. G. (1996). Inter-ethnic differences in xenobiotic metabolism. Environ. Toxicol. Pharmacol. 2, 165-170.
113. Renwick, A. G. (1998). Toxicokinetics in infants and children in relation to the ADI and TDI. Food Addit. Contam. 15, 17-35.
114. Renwick, A. G., Robertson, D. R. C., Macklin, B., Challenor, V., Waller, D. G., and George, C. F. (1988). The pharmacokinetics of oral nifedipine - A population study. Br. J. Clin. Pharmacol. 25, 701-708.
115. Ritchie, J. C., Crothers, M. J., Shah, R. R., Idle, J. R., and Smith, R. L. (1986). The metabolism of debrisoquine in man: (1) Regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis. Xenobiotica 16, 503-509.
116. Roy, S. D., Hawes, E. M., McKay, G., Korchinski, E. D., and Midha, K. K. (1985). Metabolism of methoxyphenamine in extensive and poor metabolisers of debrisoquin. Clin. Pharmacol. Ther. 38, 128-133.
117. Rudorfer, M. V., Lane, E. A., Chang, W-H., Zhang, M., and Potter, W. Z. (1984). Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br. J. Clin. Pharmacol. 17, 433-440.
118. Rutledge, D. R., Steinberg, J., and Cardozo, L. (1989). Racial differences in drug response: Isoproterenol effects on heart rate following intravenous metoprolol. Clin. Pharmacol. Ther. 45, 380-386.
119. Sakashita, M., Tamaguchi, T., Miyazaki, H., Sekine, Y., Nomiyama, T., Tanaka, S., Miwa, T., and Harasawa, S. (1993). Pharmacokinetics-of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. ArzneimForsch./Drug Res. 43, 867-872.
120. Saotome, T., Minoura, S., Terashi, K., Sato, T., Echizen, H., and Ishizaki, T. (1993). Labetalol in hypertension during the third trimester of pregnancy: Its antihypertensive effect and pharmacokinetic-dynamic analysis. J. Clin. Pharmacol. 33, 979-988.
121. Sheenan, D. M., and Gaylor, D. W. (1990). Analysis of the adequacy of safety factors. Teratology 41, 590-591.
122. Sheiner, L. B., Stanski, D. R., Vozeh, S., Miller, R. D., and Ham, J. (1979). Simultaneous modelling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther. 25, 358-371.
123. Sohn, D-R., Kwon, J-T., Kirn, H-K, and Ishizaki, T. (1997). Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'hydroxylation phenotype status. Clin. Pharmacol. Ther. 61, 574-582.
124. Sowinski, K. M., Burlew, B. S., and Johnson, J. A. (1995). Racial differences in sensitivity to the negative chronotrophic effects of propranolol in healthy men. Clin. Pharmacol. Ther. 57, 678-683.
125. Sowunmi, A., Rashid, T. J., Akinyinka, O. O., and Renwick, A. G. (1995). Ethnic differences in nifedipine kinetics: Comparisons between Nigerians, Caucasians and South Asians. Br. J. Clin. Pharmacol. 40, 489-493.
126. Strong, H. A., Oates, J., Sembi, J., Renwick, A. G., and George, C. F. (1984). Role of the gut flora in the reduction of sulphinpyrazone in humans. J. Pharmacol. Exp. Ther. 230, 726-732.
127. Tornatore, K. M., Reed, K. A., and Venuto, R. C. (1993). Racial differences in the pharmacokinetics of methylprednisolone in Black and White renal transplant recipients. Pharmacotherapy 13, 481-486.
128. Truhaut, R. (1991). The concept of the acceptable daily intake: An historical review. Food Addit. Contam. 8, 151-162.
129. Uematsu, T., Nagashima, S., Mizuno, A., Hirano, K., and Nakashima, M. (1991). Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers. J. Clin. Pharmacol. 31, 815-822.
130. van Harten, J., Burggraaf, J., Ligthart, G. J., van Brummelen, P., and Breimer, D. D. (1989). Single- and multiple-dose nisoldipine kinetics and effects in the young, the middle-aged and the elderly. Clin. Pharmacol. Ther. 45, 600-607.
131. Vettorazzi, G. (1987). Advances in the safety evaluation of food additives. Food. Addit. Contam. 4, 331-356.
132. Visser, W. H., Burggraaf, J., Muller, L. M., Schoemaker, R. C., Fowler, P. A., Cohen, A. F., and Ferrari, M. D. (1996). Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin. Pharmacol. Ther. 60, 452-460.
133. Vree, T. B., Van Den Biggelaar-Martea, M., Verwey-Van Wissen, C. P. W. G. M., Vree, J. B., and Guelen, P. J. M. (1993a). Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Biopharm. Drug Dispos. 14, 491-502.
134. Vree, T. B., Van Ewijk-Beneken Kolmer, E. W. J., Wuis, E. W., Hekster, Y. A., and Broekman, M. M. M. (1993b). Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. Pharm. World Sci. 15, 197-202.
135. Vuyk, J., Engbers, F. H. M., Lemmens, H. J. M., Burm, A. G. L., Vletter, A. A., Gladines M. P. R. R., and Bovill, J. G. (1992). Pharmacodynamics of propofol in female patients. Anesthesiology 77, 3-9.
136. Wald, J. A., Law, R. M., Ludwig, E. A., Sloan, R. R., Middleton, E., and Jusko, W. J. (1992). Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. J. Pharmacokin. Biopharm. 20, 567-589.
137. Wensing, G., Mönig, H., Ohnhaus, E. E., and Hoensch, H. P. (1991). Pharmacokinetics of encainide in patients with cirrhosis. Cardiovasc. Drugs Ther. 5, 733-740.
138. WHO (1987). Principles for the Safety Assessment of Food Additives and Contaminants in Food, Environmental Health Criteria, Vol. 70. World Health Organization, Geneva.
139. WHO (1994). Assessing Human Health Risks of Chemicals: Derivation of Guidance Values for Health-Based Exposure Limits, Environmental Health Criteria, Vol. 170. World Health Organization, Geneva.
140. Zhou, H. H., Koshakji, R. P., Silberstein, D. J., Wilkinson, G. R., and Wood, A. J. J. (1989a). Racial differences in drug response: Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared to American whites. New Engl. J. Med. 320, 565-570.
141. Zhou, H-H., Silberstein, D. J., Koshakji, R. D., and Wood, A. J. J. (1989b). Interindividual differences in β-receptor density contribute to variability in response to β-adrenoceptor antagonists. Clin. Pharmacol. Ther. 45, 587-592.
142. Zhou, H. H., Sheller, J. R., Nu, H., Wood, M., and Wood, A. J. J. (1993). Ethnic differences in response to morphine. Clin. Pharmacol. Ther. 54, 507-513.